Source comparison
CJC-1295 no DAC & Ipamorelin Dosing: Protocol Comparison
Conservative Research Protocol 150mcg Once daily (pre-bed) 1.05mg Suitable for initial tolerance assessment. Produces measurable GH pulse elevation without exceeding receptor saturation. Limited lipolytic effect due to single daily pulse. Standard Twice-Daily
This comparison does not assign a generated winner or score.
- Conservative Research Protocol
- 150mcg
- Once daily (pre-bed)
- 1.05mg
- Suitable for initial tolerance assessment. Produces measurable GH pulse elevation without exceeding receptor saturation. Limited lipolytic effect due to single daily pulse.
- Standard Twice-Daily Protocol
- 200-250mcg
- Twice daily (morning + pre-bed)
- 2.8-3.5mg
- Most effective balance between GH pulse frequency and amplitude. Aligns with natural circadian secretion patterns. Produces sustained IGF-1 elevation measurable after 3-4 weeks.
- Aggressive High-Frequency Protocol
- 200mcg
- Three times daily (morning, post-workout, pre-bed)
- 4.2mg
- Higher weekly exposure but blunted per-dose GH response due to somatostatin rebound between closely-spaced injections. Marginal benefit over twice-daily with increased injection burden.
- Single High-Dose Protocol (avoid)
- 400-500mcg
- Once daily
- Exceeds GH pulse saturation threshold. No additional benefit over 200-250mcg doses but significantly higher side effect incidence (water retention, transient insulin resistance). Wasteful dosing strategy.
- The twice-daily protocol at 200-250mcg per peptide consistently demonstrates the highest efficacy-to-side-effect ratio across published research. Weekly peptide consumption totals 2.8-3.5mg per compound. Substantially lower than the 5-7mg weekly doses commonly promoted in non-clinical sources, yet produces equivalent or superior fat loss outcomes when timing and purity are controlled.